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Background: Procalcitonin (PCT) is widely used in critically ill patients to diagnose clinically significant infection and
sepsis. Aim of this study was to evaluate the prognostic value of PCT in comparison to white blood cell count
(WBC) and C-reactive protein (CRP) for clinical outcome and its correlation with microbiological etiology in patients
with infective endocarditis (IE).
Methods: A retrospective single-center analysis was performed from 2007 till 2009. All patients were diagnosed
having IE according to Duke standard criteria. Before starting antibiotic therapy, WBC, CRP and PCT were measured
and blood cultures were taken for microbiological diagnosis of the etiological pathogen. Patients were followed up
during in-hospital stay for poor outcome, defined as death or serious complications due to IE.
Results: During the study period 50 patients (57 ± 17 years, 72% male) fulfilling Duke criteria for IE were identified.
In all patients PCT measurements before start of antibiotic therapy were available. In ROC analysis, a cut-off for
PCT > 0.5 ng/mL was most accurate for the prediction of poor outcome with a sensitivity of 73% and specificity of
79%, a positive predictive value of 79% and a negative predictive value of 73%. Patients with a PCT > 0.5 ng/mL
had an odds ratio of 12.8 (95% CI 2.5 – 66.2) for finding Staphylococcus aureus in blood cultures.
Conclusions: For the first time, this study shows that in IE, an initial value of PCT > 0.5 ng/mL is a useful predictor
of poor outcome, i.e. death or serious infectious complications. PCT > 0.5 ng/mL should raise the suspicion of
Staphylococcus aureus as the etiological pathogen, whereas PCT levels < 0.5 ng/mL make staphylococcal
infection unlikely.Background
The term “infective endocarditis” (IE) is used to describe
a set of clinically different entities. The morbidity and
mortality of IE remains high. Right sided native valve IE
generally takes a more benign course and even short-term
antibiotic regimen can be successful [1]. Prosthetic valve
IE, by contrast, is a severe, life-threatening disease
requiring different therapeutic measures [2]. In IE,
known predictors of clinical outcome are age, vegetation
size and the causative organism [3-7]. Still, individual
clinical courses differ significantly.
Thus, a biomarker for the prediction of prognosis and
the identification of the etiological pathogen at the initial
evaluation of patients with IE would be very valuable
and helpful. A biomarker strategy could allow early
identification of high-risk IE patients needing more* Correspondence: ccornelissen@ukaachen.de
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distribution, and reproduction in any mediumaggressive therapy. Up to now, C-reactive protein (CRP)
has been studied as a predictor of clinical course in IE.
Serial measurements showing elevated serum CRP
levels > 122 mg / dl one [8] and > 62 mg / dl four [9]
weeks after initiation of treatment have shown to predict
poor outcome, but initial serum levels of CRP at time of
diagnosis failed to predict the clinical course [8-10].
Procalcitonin (PCT) is widely used in critically ill
patients to diagnose clinical significant infection and
sepsis. In IE patients undergoing heart valve replacement,
PCT showed typical postoperative kinetics with a peak
3 days after surgery but failed to predict complications of
surgery [11]. It has also been found to be a valuable
diagnostic marker in IE [12,13], but its prognostic value
has not yet been investigated.
The aim of this study was therefore to evaluate the
prognostic value of PCT for clinical outcome including
death and serious complications and its correlation with
microbiological etiology in patients with IE.tral Ltd. This is an Open Access article distributed under the terms of the
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Patients
We performed a retrospective single-centre study at a
German university hospital with large departments of
cardiology and cardiac surgery. Data from cardiologic
patients were analysed from January 1st 2007 until
December 31st 2009 in accordance with the Helsinki
declaration. Written approval was obtained from the
ethics committee of the RWTH Aachen university
hospital for this study. All patients with documented
diagnosis of IE were included into the study. Clinical
documentation was evaluated for the presence of Duke
endocarditis service criteria [14]. Patients that did not
match Duke criteria for definite IE were excluded from
the analysis. All patients that were positive for definite IE
according to the Durack criteria also fulfilled the modified
Duke criteria for definite IE [15].
In house medical records for eligible patients were
obtained. All clinical relevant data from the patients
were stored in an electronic database. Data set included
patients’ characteristics, laboratory measurements, echocar-
diography, microbiological findings, pathological findings,
need for surgical valve replacement of the infected valve
and clinical course of the disease. Detection of microbial
pathogens was performed according to standard methods
and established microbiological guidelines. All patients
were followed-up until demission from hospital.
During the study period 67 patients with the diagnosis
of IE were treated at our hospital. In the retrospective
analysis nine patients failed to match Duke endocarditis
service’s criteria for IE. In patients fulfilling the Duke
criteria, eight had no initial PCT measurement before
start of antibiotic therapy and were therefore excluded
from the study. In total, 50 patients qualified for further
analysis.
Determination of PCT, CRP and leukocyte count
Leukocyte count (WBC) was determined by the hospital
laboratory. Serum CRP (normal < 5 mg/dl) was measured
by nephelometry with a commercially available assay
(Behring Diagnostics, Marburg, Germany). Serum PCT
(normal < 0.1 pg/nl) was determined by an immunofluor-
escent assay (B.R.A.H.M.S PCT sensitive KRYPTOR, B.R.
A.H.M.S AG, Henningsdorf, Germany). The assay requires
50 μl of serum, EDTA or heparin plasma, has a functional
assay sensitivity (defined as lowest value with an interassay
CV <20%) of 0.06 ng/mL and a lower detection limit of
0.02 ng/mL. Laboratory measurements were performed in
a blinded fashion without knowledge of the microbiological
results or the clinical status of the patient. PCT, CRP and
WBC were measured on admission before initiation of
antibiotic therapy. Patients without measurement of PCT,
CRP and WBC before initiation of antibiotic therapy were
excluded from the study.Clinical outcome
The primary end point of this study was poor clinical
outcome, which was defined as either death or serious
complications during hospitalisation. Serious complica-
tions included infectious complications (defined as
septic arthritis, meningitis, osteomyelitis, visceral abscess,
peripheral emboli, mycotic aneurysm, septic pulmonary
infarction and intracranial hemorrhage or infarction),
cardiac failure, severe cardiac rhythm disorders, septic
shock and need for surgical replacement of the infected
valve. This combined endpoint was also used in previous
larger studies in this field - e.g. by Verhagen et al. [8].Statistics
Continuous variables are expressed as mean ± SD or
median and interquartile range in parenthesis unless
stated otherwise. Two group nonparametric comparisons
were calculated by the Mann–Whitney U-test. Frequency
comparison was done using the χ2-test. To compare the
predictive value of WBC, CRP and PCT we constructed
Receiver-operating-characteristics (ROC) curves and
determined the area under the curve (AUC). The outcome
variable was event-free survival (no death, no serious com-
plication) until demission from hospital. The operative
characteristics of PCT, CRP and WBC were assessed
calculating sensitivity, specificity, positive and negative
predictive values and the positive and negative likelihood-
ratio. Kaplan Meier survival curves were generated to
visualize the distribution of times from baseline to death
or serious complications, and log-rank test was performed
to compare the event-free survival curves between groups.
All statistical tests were 2-tailed and a p-value < 0.05 was
considered statistically significant. Data analysis was
performed using commercially available software (SAS
enterprise guide version 4, SAS Institute Inc., NC, USA).Results
The study population had a mean age of 57 ± 17 years
(range 23 to 87 years), and 72% were male (Table 1). All
patients were hospitalised. In most cases the aortic
(58%) or mitral valve (28%) were involved. The mortality
rate of the study population was 22% (n = 11). At follow-up
18 patients suffered from serious complications (for details
please see Table 2). According to international guidelines,
appropriate antibiotic treatment was initiated as early as
possible in all patients with IE or high probability of
IE. Empiric antibiotic therapy was administered as a
combination therapy and pathogen-specific therapy was
initiated as soon as antibiograms were available. The
mean length of stay in hospital was 29 ± 17 days (range
3 to 65 days) for patients with event-free survival and
38 ± 28 days (range 1 to 120 days) for patients with
adverse events.
Table 1 Patients characteristics
Characteristic Total Adverse event Event-free survival p-value
(n = 50) (n = 27) (n = 23)
Age, (years ± SD) 57 ± 17 52 ± 16 62 ± 16
Male / Female (n) 36 / 14 18 / 9 18 / 5
Charlson Comorbidity Score age adjusted
(Median, interquartile range) 1 [0 – 4] 1 [0 – 4] 0 [0 – 4,5] 0.89
Diabetes Mellitus (n) 8 6 2 0.19
Immunocompromised* (n) 1 1 0 –
i.v. Drug Abuse (n) 6 6 0 0.02
Conditions at diagnosis (n)
Vasopressors 15 12 3 0.02
Mechanical ventilation 11 8 3 0.16
ICU 17 12 5 0.09
Site of infection (n, %)
Aortic valve 29 (58%) 13 16 0.58
Pulmonary valve 1 (2%) 1 0 –
Mitral valve 14 (28%) 8 6 0.59
Tricuspid valve 6 (12%) 5 1 –
Prosthetic valve (n) 11 8 3 0.16
Known valvular disease (n) 13 7 6 1
Echocardiography
Perivalvular abscedation (n) 5 4 1 0.22
Severe Insufficiency (n) 21 8 13 0.05
Size of vegetation
(2D, mm2, median, interquartile range) 103 [32 – 179] 105 [54 – 195] 98 [27 – 162] 0.22
Causative organism (n, %)
Staphylococcus aureus 16 (32%) 15 1 < 0.01
Staphylococci other than aureus 7 (14%) 2 0 –
B-Streptococci 2 (4%) 0 2 –
Streptococci other than B 11 (22%) 2 9 0.03
Enterococcus faecium 5 (10%) 2 3 –
Actinomyces israelii 1 (2%) 0 1 –
No proven causative organism 7 (14%) 4 0 –
Data are presented as number of cases (percentages of total number).
*Patients with human immunodeficiency virus, acquired immunodeficiency syndrome, solid organ or bone marrow transplantation, receiving steroids
(>20 mg of prednisone or equivalent for >1 month), or recent chemotherapy (>1 month).
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Median PCT levels (Table 3) on admission of patients
with death or serious complications were significantly
higher compared to those in event-free survivors (1.7
[0.6 – 8.6] vs. 0.2 [0.1 – 0.3] ng/mL, p < 0.01, Figure 1a).
The respective values for CRP were 93 [63 – 193] vs. 45
[19 – 86] mg/L, p < 0.01 (Figure 1b) and for WBC 11.6
[7.9 – 16.0] vs. 8.7 [7.4 – 11.1] G/L, p < 0.01 (Figure 1c).
The accuracy of WBC, CRP and PCT to predict death
or serious complications at follow-up according toreceiver operating characteristics is given in Figure 2.
The AUC was highest for PCT (0.85 ± 0.05), which was
significantly higher compared to the AUC for CRP
(0.73 ± 0.07, p < 0.01) and WBC (0.69 ± 0.07, p < 0.01).
In ROC-analysis, a PCT cut-off > 0.5 ng/mL was found
to be the best predictor of adverse outcome with a
sensitivity of 73%, specificity of 79%, positive predictive
value of 79% and negative predictive value of 73%.
Figure 3 shows Kaplan Meier survival curves of low risk
patients and high risk patients stratified according to a
Table 2 Clinicial outcome and complications
Adverse outcome 27 (54%)
Death 11 (22%)
Serious infectious complication 18 (36%)
meningitis 6 (12%)
peripheral embolisation 7 (14%)
visceral abscess 4 (8%)
osteomyelitis 3 (6%)
Other serious complication 7 (14%)
cardiac failure 2 (4%)
severe cardiac rhythm disorders 0 (0%)
septic shock 5 (10%)
Need for valve replacement 29 (58%)
(aortic n = 19, mitral n = 7, pulmonary n = 1, tricuspid n = 2)
Data are presented as number of cases (percentages of total number).
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complications were significantly lower in patients with
a PCT ≤ 0.5 ng/mL compared to patients with PCT
values > 0.5 ng/mL.Microbiology and inflammatory markers
The causative pathogen was found in 43 (86%) patients
(Table 1). Patients with IE due to an infection with
Staphylococcus aureus compared to other pathogens
(Figure 4) showed no significant differences in values of
PCT (2.1 [0.9 – 2.1] vs. 0.5 [0.2 – 2.1] ng/mL, p = 0.36),
CRP (169 [48 – 230] vs. 86 [33 – 163] mg/L, p = 0.11)
and WBC (11.7 [10.6 – 15.9] vs. 10.1 [7.2 – 13.4] G/L,
p = 0.28). At univariate analysis, serum PCT > 0.5 ng /mL
showed an odds ratio of 12.8 (95% CI 2.5 to 66.2) to
differentiate IE due to Staphylococcus aureus from IE due
to other etiology.Discussion
The main findings of our study include 1) that levels of
PCT, CRP and WBC are significantly higher in patients
that experience death or serious complications in IE, 2)
PCT is the best predictor of poor clinical outcome, 3)Table 3 Median (interquartile range) levels of biomarkers
Characteristic Adverse event Event-free survival p-va
(n = 26) (n = 24)
Procalcitonin 1.7 0.2 < 0
(ng/mL) [0.6 – 8.6] [0.1 – 0.3]
CRP 93 86 < 0
(mg/L) [63–193] [19–86]
WBC 11.6 8.7 <0
(G/L) [7.9 – 16.0] [7.4 – 11.1]
Legend: IE: infective endocarditis; CRP: C-reactive protein; WBC: white blood cell couinitial biomarker measurement does not allow individual
prediction of microbiological etiology of IE.
The current diagnostic strategy for IE follows the
Duke criteria [14,15]. It requires typical microorganisms
grown from at least 2 separate blood cultures and
evidence of endocardial involvement, usually documented
by echocardiography. Despite these criteria the definitive
diagnosis of IE in daily clinical practice requires expertise
and time. Therefore, it would be very helpful if we had a
biomarker for the rapid evaluation of the presence or
absence of IE in suspected cases.
There are some previous studies with respect to IE
and inflammatory biomarkers. All have in common that
the biomarkers, especially PCT, are used for the diagnosis
or differential diagnosis of IE. Müller et al. conducted a
prospective cohort study in 67 consecutive patients with
the suspicion of IE [13]. Comparable to our study, the
diagnosis of IE was established by application of the Duke
criteria. In 21 patients with confirmed IE, PCT was signifi-
cantly higher in patients with IE (median 6.56 ng/mL) than
in those with other final diagnoses (median 0.44 ng/mL).
The AUC for PCT (0.856) to predict IE was significantly
higher compared to CRP (0.657). Interestingly, PCT was
the only significant independent predictor of IE on
admission in multivariate analysis. Another study by
Knudsen et al. found similar results [16]. PCT was
higher in patients with IE compared to those where IE
diagnosis was rejected. In this study independent determi-
nants of high PCT were positive blood culture with
endocarditis-typical microorganisms, temperature ≥38°C,
symptoms ≤ 5 days, immunocompromised status and male
gender. However, the range of PCT was that wide, that a
suitable PCT threshold for diagnosing or excluding IE
could not be established in this study.
Our study is the first to evaluate inflammatory
biomarkers at initial presentation for the prediction
of prognosis of IE in terms of death and serious
complications, which has not been addressed in previous
studies. Previous studies included either the analysis of a
variety of risk factors [17] or serial measurements of CRP
[8] or PCT [18] to predict prognosis of IE. Most of the
proposed risk factors for poor prognosis in IE had to belue Staph. aureus IE Non Staph. aureus IE p-value
(n = 16) (n = 14)
.01 2.1 0.5 0.36
[0.9 – 10.2] [0.2 – 2.1]
.01 169 86 0.11
[48–230] [33 – 163]
.01 11.7 10.1 0.28
[10.6 – 15.9] [7.2 – 13.4]
nt.
Se
ns
iti
vi
ty
1-Specificity 
WBC
CRP
PCT
0 0.1 0.2    0.3  0.4  0.5   0.6  0.7  0.8 0.9   1
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
Figure 2 Receiver operating curves for white blood cell count,
C-reactive protein and Procalcitonin for the prediction of
adverse events.
0
50
100
150
200
250
300
No Complication Complication
CR
P 
(m
g/
L)
B: C - reactive protein
p < 0.01
0
5
10
15
20
25
30
No Complication Complication
W
B
C 
(G
/L)
A: White blood cell count 
p < 0.01
0
5
10
15
20
25
30
No Complication Complication
PC
T 
(n
g/
m
l)
C: Procalcitonin
p < 0.01
Figure 1 White blood cell count, C-reactive protein and
Procalcitonin levels for patients with and without serious
complications.
Cornelissen et al. BMC Infectious Diseases 2013, 13:272 Page 5 of 7
http://www.biomedcentral.com/1471-2334/13/272rejected over time. The remaining factors that are indicative
for a poor prognosis comprise a) development of com-
plications, e.g. heart failure, septic emboli or persistent
bacteremia, b) indicators of excessive valve destruction,
e.g. vegetation size or perivalvular abscess formation, c)
concomitant diseases, e.g. diabetes mellitus, d) the causa-
tive organism and e) increasing age [19]. Older patients
are less likely to undergo surgery for IE because of
comorbidities, even if surgery is indicated. Excessive valve
destruction makes surgery more often necessary.
We were the first to show that PCT levels on admission
of patients with death or serious complications were
significantly higher compared to those in event-free
survivors. The accuracy of PCT to predict death or serious
complications at follow-up was superior to CRP and
WBC. A PCT cut-off > 0.5 ng/mL was the best predictor
of adverse outcome. If our findings are confirmed in
future prospective intervention studies, PCT might be-
come part of a tool for risk assessment in IE, with PCT
levels ≤ 0.5 ng/mL indicating low-risk patients. In high-risk
patients with PCT levels > 0.5 ng/mL, increased attentionto complications of IE and closer medical follow-up
may be indicated. This cut-off for PCT > 0.5 ng/mL is
similar to the PCT cut-off used for the diagnosis of
sepsis, which Kocazeybek et al. also used in their study
on serial measurements of PCT [18] without further
statistical evaluation. This seems plausible because IE is
an intracardiac infection with continuous bacteremia.
As a result PCT levels in IE are higher than in other
infections like e.g. lower respiratory tract infections,
where a lower PCT cut-off of 0.25 ng/mL is applied
whereas they are comparable to sepsis, where a PCT
cut-off of 0.5 ng/mL is used [20].
As a marker for poor outcome in cardiac diseases,
B-type natriuretic peptide has been extensively studied.
Its initial levels do show association to clinical outcome in
infective IE, but adequate analysis with respect to diagnostic
cut-offs and diagnostic accuracy is lacking [21,22].
A tool to predict individual prognosis in a severe disease
such as IE would allow for more rationale resource alloca-
tion in the early and the late stages of treatment. Initially,
allocation to different setting of care such as intensive,
intermediate and standard care wards might be more
straightforward.
Over the past decade, PCT has gained importance in
the diagnosis of severe systemic infection and sepsis [23].
In lower respiratory tract infections and exacerbation of
chronic obstructive lung disease, it is used to guide
antibiotic therapy [24]. We hypothesized that PCT
might be useful to predict microbiological etiology of
IE, which would be helpful for the choice of adequate
antibiotic therapy. One of the most powerful indicators
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associated with more frequent rapid course of the disease
and more complications. This was also true in our study
cohort, where 15 out of 16 patients (94%) with Staphylo-
coccus aureus IE experienced serious complications. The0
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Figure 4 White blood cell count, C-reactive protein and
Procalcitonin levels for Staph. aureus and other causative
organisms.results of blood cultures are normally not available at the
time of initiation of antibiotic therapy. If blood cultures
become positive the microbiological results are usually
available within 24 to 48 hours. According to the AHA
guidelines, the choice of appropriate antibiotic therapy for
IE depends on the causative microorganism. Jereb et al.
found highest PCT levels in patients with Staphylococcus
aureus endocarditis [12]. We also found that patients with
IE due to Staphylococcus aureus were more likely to show
higher values of PCT, CRP and WBC. In our study, the
odds ratio for patients with PCT > 0.5 ng /mL was 12.8
for the prediction of Staphylococcus aureus IE. However,
inflammatory markers did not allow an individual
prediction of microbial etiology of IE. As a consequence
an empiric antibiotic therapy for IE has to be started
irrespective of the levels of the inflammatory markers.
Antibiotic therapy should be adapted after blood culture
results are available.
In lower respiratory tract infections there are several
trials that clearly demonstrated that antibiotic therapy
can be guided by PCT measurements [25-27]. This results
in a reduction of antibiotic consumption compared to a
standard therapy without PCT guidance. In IE there is no
such trial with a PCT algorithm for guidance of antibiotic
therapy. Taking into account the high risk of recurrence of
IE, such a PCT algorithm should be different from the one
used for lower respiratory tract infections. In patients with
a high probability of IE, antibiotic therapy would not be
withheld from any patient, irrespective of the PCT value.
However, one might speculate that it might be possible to
stop antibiotic therapy successfully, if PCT values have
fallen for some weeks below a specific cut-off value.
The present study has some limitations. Despite inten-
sive microbiological diagnostics, the etiology remained
unknown in 14%. This problem is well known from
other IE studies [8-10]. We did not perform serial PCT
measurements. Therefore we were not able to correlate
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sample size did not allow for reliable multivariate
analysis. A prospective multicentre study is needed to
address these limitations.
Conclusions
Appropriate biomarkers for predicting prognosis in IE
would be helpful for optimal management of this disease
and rational resource allocation. This study shows that
PCT is a possible predictor of poor prognosis. Measure-
ment of PCT, CRP, and WBC however do not allow an
individual prediction of microbial etiology of IE.
PCT might be a valuable tool helping clinicians – in
combination with complimentary clinical data - to assess
a patient’s risk profile and to improve therapeutic
decision making.
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